A recent report demonstrated that JC virus (JCV) employs serotonin receptor 2A (5HT 2A R) to infect the glial cells. To assess the ability of a potent 5HT 2A R blocker, risperidone, to inhibit JCV infection, the authors treated primary human fetal glial (PHFG) cells in vitro with risperidone for 24 h and inoculated with JCV(Mad1). There was no significant difference in JCV genome copies or mRNA transcripts and protein expression in treatmentnaïve and risperidone-treated PHFG cells. These data indicate that risperidone does not inhibit JCV(Mad1) attachment, internalisation, and replication in PHFG cells, and 5HT 2A R blockers may not be effective in treating progressive multifocal leukoencephalopathy (PML). Journal of NeuroVirology (2008) 14, 448Á454.
when treated with highly active antiretroviral therapy (HAART) (Antinori et al, 2003; Lima et al, 2007) , in the post-HAART era incidence of PML has not significantly changed (Antinori et al, 2001) , and PML currently is the second most frequently diagnosed neurological disorder among AIDS patients (Antinori et al, 2001) . Few reports have demonstrated beneficial effect of cytosine arabinoside (Aksamit, 2001; De Luca et al, 1999; Elphick et al, 2004) and cidofovir (De Luca et al, 2001) in treating PML patients; however, studies have concluded that cytosine arabinoside (Enting and Portegies, 2000) and cidofovir (Marra et al, 2002; Wyen et al, 2004) therapy have no significant therapeutic benefit. Although clinical outcome among PML patients treated with interferon (IFN) is controversial (Colosimo et al, 1992; Geschwind et al, 2001; Huang et al, 1998; Nath et al, 2006) , IFN is effective in in vitro inhibition of JCV replication and intrathecal infusion of IFN may be beneficial as an adjunct therapy for PML (Co et al, 2007) . It is important to note that there is currently no proven therapy or vaccine available for treatment and prevention of the fatal disease, PML.
A recent study demonstrated that the chimera polyomavirus JC (Mad-1/SVED) consisting of JCV-SV40 (simian virus 40) promoter-enhancer sequences in the backbone of JCV coding region sequences employs the serotonin receptor 2A (5HT 2A R) to infect SVG-A cells, a subclone of transformed human fetal glial cells by an origindefective SV40 mutant (Elphick et al, 2004) . Altschuler and Kast (2005) have suggested that newer, safer antipsychotic drugs, such as risperidone, ziprasidone, and olanzapine, with significantly more potent 5HT 2A R antagonist activity, may be useful in treating or preventing PML. Because half of the healthy adult population shed large amounts of JCV in the urine (Agostini et al, 1996 (Agostini et al, , 1997 (Agostini et al, , 2001 Shah et al, 1997) , this provides an unique opportunity to test safe and easy-to-tolerate drugs such as risperidone and mirtazapine for anti-JCV activity, using urinary tract clearance of JCV as an additional surrogate marker for potential in treating PML (Focosi et al, 2007b) . Sure enough, these drugs were tested and some recent case reports have suggested survival benefit among HIV-naïve PML patients treated with risperidone (Focosi et al, 2007) or mitrazepam (Owczarczyk et al, 2007; Verma et al, 2007; Vulliemoz et al, 2006) and demonstrated clearance of JCV from blood (Focosi et al, 2007) . It is possible that 5HT 2A R blockers may be effective in controlling JCV replication in vivo. However, it was unclear whether the beneficial effect observed in these patients was the result of modification of immunosuppressive treatment leading to immune reconstitution or was contributed by the 5HT 2A R blockers risperidone or mirtazapine. We recently demonstrated that human brain microvascular endothelial (HBMVE) cells can be infected with JCV, independent of 5HT 2A R (Chapagain et al, 2007) . Although, primary human fetal glial (PHFG) cells in vitro express 5HT 2A R mRNA transcripts and protein (Chapagain et al, 2007) , it remains yet unclear whether oligodendrocytes, the primary target cells in vivo, express 5HT 2A R (Santagata and Kinney, 2005) and if 5HT 2A R blockers inhibit JCV replication in oligodendrocytes and are useful in preventing or treating PML.
To assess the effect of risperidone on JCV infection and replication in PHFG cells, we first tested the toxicity of risperidone to the PHFG cells. PHFG cells were isolated and cultured from therapeutically aborted 10-to 14-weeks-old fetal brains, as described previously, after obtaining approval from the institutional review board of the Kapi'olani Medical Center for Women and Children, Honolulu, Hawai'i (Chapagain et al, 2006; Padgett et al, 1977) . Approximately 5000 PHFG cells were grown per well in a 96-well plate either with medium alone or in the continuous presence of risperidone (Risperdal oral solution, catalog number: NDC 50458-305Á03; Janssen Pharmaceutica N.V., Beerse, Belgium). Risperidone*a monoaminergic antagonist for serotonin type 2, dopaine type 2, a-1 and a-2 adrenergic, and H1 histaminergic receptors, is widely used to treat psychotic disorders and has high affinity for 5HT 2A R (Morisset et al, 1999) . The medium, with or without risperidone, was changed every 5th day and cell proliferation and viability were determined by the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI) on days 0, 5, 10, and 15 after incubation with risperidone. The absorbance in each well was measured according to the manufacturer's protocol at 490 nm using a multiplate reader (Victor 3 ; Perkin Elmer, MA), and was expressed as percentage of untreated cells. Risperidone in concentration up to 200 ng/ml was nontoxic to PHFG cells in vitro and PHFG cells untreated or treated with risperidone for up to 15 days did not show any change in the cell viability based on the cell proliferation assay ( Figure 1 ).
We next examined the effect of risperidone in PHFG cells infected with JCV (Mad1). PHFG cells grown to 70% to 80% confluency in each 35-mm culture plate were incubated for 24 h either with medium alone or with medium containing 12.5, 50, or 200 ng/ml of risperidone and inoculated with JCV containing 1.96 (9 0.53) ) 10 9 and 1.36 (9 0.42) ) 10 9 TAg and VP-1 genome copies, respectively, for 2 h in the absence or continuous presence of risperidone. Cells were harvested on days 0, 5, 10, and 15 after inoculation, and DNA (Qiagen QIAprep Spin Miniprep Kit; catalog number 27104) and RNA (Qiagen RNeasy Plus kit; catalog number 74134), extracted from 35-mm plates, were eluted in 100 and 50 ml of elution buffer, respectively. cDNA was Risperidone in JCV infection synthesized from 0.5 mg of total RNA using Bio-Rad's iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) in a 20-ml reaction mixture. Two microliters of template DNA or cDNA were amplified and quantitated in the Bio-Rad iCycler iQ Multicolor Real-Time PCR Detection System using Bio-Rad 2 ) iQ Taqman supermix, 12.5 pmol each of forward and reverse primers and 5 pmole of probes specific for JCV TAg (forward: 5'-AGA GTG TTG GGA TCC TGT GTT TT-3', reverse: 5'-GAG AAG TGG GAT GAA GAC CTG TTT-3', and probe 5'-/FAM/TCA TCA CTG GCA AAC ATT TCT TCA/BHQ-1/-3') or VP-1 (forward: 5'-ACT GTC CAT ATT TGT CAA CGT ATC-3', reverse: 5'-AAG GTC CAG CTA AGG AAA AGG-3', and probe 5'-/FAM/TCT GGG TCC CCT GGA AGC TCC TCT/BHQ-1/-3') in a final reaction volume of 20 ml. Thermal cycling was initiated with the first denaturation step of 4 min at 958C, followed by 40 cycles of 958C (30 s for TAg or 10 s for VP-1) and 608C (45 s for TAg) or 588C (10 s for VP-1). Copies of JCV TAg or VP-1 genomes or mRNA transcripts in experimental samples were calculated from the standard curve and expressed as copies of viral genome per 35-mm plate or mRNA transcripts per microgram of total RNA.
Based on the TAg and VP-1 genome copies, approximately 11.2% (SD 92.6%) and 9.3% (SD 90.98%), respectively, of JCV was attached or internalized into PFFG cells at 2 h (0 day time point in Figure 2A and B) after inoculation with JCV. However, there was no significant (P !.05) difference in the JCV TAg (Figure 2A ) or VP-1 ( Figure 2B ) genome copies recovered at 2 h after inoculation from PHFG cells untreated or treated with risperidone at concentrations of 12.5, 50, or 200 ng/ml, suggesting that there was no effect of risperidone on JCV attachment or internalization into PHFG cells. Similar numbers of JCV TAg and VP-1 genome copies were recovered from drug-naïve and risperidone-treated PHFG cells harvested at different time points after inoculation (Figure 2A and B) , suggesting that risperidone has no effect in JCV genome replication. There was no significant difference (P ! .05) in the JCV early (TAg) or late (VP-1) gene mRNA transcripts ( Figure 2C 
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Because risperidone did not have significant effect on JCV replication, it was important to demonstrate that the risperidone we employed was functional. We therefore conducted receptor-binding assays on membrane preparation of HEK-293 cells transfected with 5-HT 2A R pDNA. HEK-293 cells were transfected with the open reading frame (ORF) of human 5-hydroxytryptamine receptor 2A (GeneBank accession no. NM_000621; University of Missouri cDNA resource center, Rolla, MO) using Lipofectamine 2000 transfection reagent (Invitrogen, catalog number 11668Á019), according to the manufacturer's instructions. Cells were either untreated or treated with 12.5, 50, 200, or 1000 ng/ml of risperidone for 24 h, harvested at 72 h after transfection, RNA was extracted, and 0.5 mg of RNA was employed for cDNA synthesis. 5-HT 2A R gene was amplified using the 5-HT 2A R primer pair (forward: GGC ACA CGG GCC AAA TTA GC and reverse: TTG CTC ATT GCT GAT GGA CTG C) in a GeneAmp Thermal Cycler 9700 (Perkin-Elmer, Wellesley, MA) with 5 ml of cDNA in a 50-ml reaction mixture containing 1.0 U AmpliTaq Gold (Applied Biosystems, Foster City, CA), polymerase chain reaction (PCR) buffer with 1.5 mM MgCl 2 , 0.2 mM dNTPs, and 0.4 M of each primer. An initial pre-PCR denaturation step (4 min at 958C) was followed by 35 three-step PCR cycles of denaturation (958C for 10 s), annealing (588C for 20 s), and elongation (728C for 30 s), followed by a final elongation step (728C for 10 min). Simultaneously, PCR was conducted using primers for house keeping gene GAPDH (forward: AGT TAG CCG CAT CTT CTT TTG C and reverse: CAA TAC GAC CAA ATC CGT TGA CT) as an internal control (Chapagain et al, 2007) . The amplicons were electrophoresed on a 2% agarose gel, and the ethidium bromide fluorescence was visualized after scanning with a Bio-Rad Molecular Phosphorimager.
Our data suggest that transfected HEK-293 cells expressed 5-HT 2A R transcripts, and risperidone treatment at all concentrations does not inhibit 5-HT 2A R transcripts levels ( Figure 4A (Decker et al, 2004) . Briefly, HEK-293 cells were seeded on 100-mm plates and transfected with 12 mg 5-H 2A R and 24 ml of Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions. At 72 h after transfection, cells were washed with 1 ) PBS, scraped, and centrifuged at 1000 rpm for 10 min. The pellet was homogenized in 50 mM Tris-HCl (pH 0 7.7) with a polytron homogenizer, centrifuged at 20,000 rpm, resuspended with 25 mM Tris-HCl (pH 07.7), and aliquoted and stored at -808C after measuring protein concentration by the Bradford assay. On the day of assay, the protein preparation was thawed and adjusted to 5 mg protein/80 ml with 25 mM Tris-HCl (pH 7.7) and 0.8 ml of cell homogenate (0.05 mg/protein/well) was added to wells containing 100 ml of the risperidone at the final concentration of 0.125, 1.25, 12.5, 50, or 200 ng/ml or buffer, and 100 ml of [ 3 H]ketanserin (2.0 nM final concentration). The mixture was incubated at 378C for 30 min, reaction was stopped by rapidly filtering through the glass fiber filter paper, washed four times with ice-cold 50 mM Tris-HCl (pH 07.7) using FilterMate Cell Harvester (Packard Instrument, Meriden, CT), dried for 4 h, and the radioactivity was measured using a Tri-Carb 2900TR Scintillation Counter (Perkin-Elmer). Nonspecific binding was determined by incubating with 10.0 mM ritanserin. Risperidone at concentrations of 0.125, 1.25, 12.5, 50, or 200 ng/ml reduced [ 3 H]ketanserin binding to 67.58% 9 4.28%, 13.48% 9 2.35%, 0.21% 9 1.1%, 0.48% 9 3.28%, and 0.16% 9 0.26% of the binding of untreated control, respectively ( Figure  4D ). These data indicate that risperidone significantly reduces ketanserin binding in a dose-dependent manner ( Figure 4D ), and confirms that the risperidone we employed is functional.
Our data suggest that risperidone, a potent 5HT 2A R blocker (Altschuler and Kast, 2005; Morisset et al, 1999) , does not inhibit JCV entry and replication in PHFG cells in in vitro. This result is consistent with our previous study demonstrating 5HT 2A R-independent JCV infection of HBMVE cells (Chapagain et al, 2007) ; however, it contradicts with the previous study that suggested JCV uses 5HT 2A R to infect glial cells (Elphick et al, 2004) . This inconsistency may be attributed to the use of different JCV strains or cells. Whereas Elphick and colleagues employed chimeric JCV that has SV40 promoter, in this study, we used the JCV(Mad1), which is predominantly found among brains of PML patients (Dubois et al, 2001) . It is possible that chimeric JCV(Mad-1/SVED) behaves differently than JCV(Mad1) found in the PML brains. Moreover, we used PHFG cells, which most closely resemble the JCV target cells population in vivo, whereas Elphick et al used SVG-A cells, a subclone of SV40 transformed human fetal glial cells (Elphick et al, 2004) . It is also possible that JCV may use different receptors to infect different target cells. Although, PHFG cells in vitro express 5HT 2A R mRNA transcripts and protein (Chapagain et al, 2007) , 5HT 2A R immunoreactivity was not detected in oligodendrocytes of rat spinal cord (Maxishima et al, 2001) , and there is as yet no clear report demonstrating that human oligodendrocytes express 5HT 2A R (Santagata and Kinney, 2005) . Interestingly, a recent publication also suggests that there was only a modest effect, if any, of risperidone on JCV infection of SVG-A cells and, more importantly, there was no significant difference in JC viral load between 5-HT 2A R blockerÁtreated and -untreated SVG-A cells, which concur with our findings (O'Hara and Atwood, 2008) . It is possible that human oligodendrocytes may not express 5HT 2A R, JCV may employ receptors other than 5HT 2A R to infect oligodendrocytes, and 5HT 2A R blockers may not be effective in treating PML. Further studies are essential to demonstrate expression of 5HT 2A R in oligodendrocytes, the primary target cells of JCV in the human brain, and to document the effectiveness of 5HT 2A R blockers in reducing JCV viral load in clinical trials before widespread use of 5HT 2A R blockers for treatment or prevention of PML.
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